Check our recent publication: B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
#mmsm

➡️onlinelibrary.wiley.com/doi/full/10.10…
Talquetamab 1st➡️BCMA BsAb or CAR-T
✅Median F/U:9.5 months(range:6–24mo)
✅Median PFS: 5.5 months (range:1–10mo)

Dynamic Prognostic Survival Model Incorporating PROs for TIE Patients With MM with Hsien Seow PhD Amaris Balitsky Tanya Wildes MD Alissa Visram. Thank you Leukemia & Lymphoma Society of Canada for funding Canadian research with ICES Myeloma Canada McMaster Research Hamilton Health Sciences ECRI - ESCARPMENT CANCER RESEARCH INSTITUTE…

In our piece just out in NatureRevClinOncol, Aaron Goodman - “Papa Heme” and I draw attention to overtreatment of multiple myeloma and its precursor states and highlight how de-escalation is an urgent need in clinical practice and in trials.

#mmsm

rdcu.be/dFqsN

Check out my editorial: Clinical Trials of T-Cell Re-Directing Therapy in Plasma Cell Precursor Conditions #mmsm

➡️free access: authors.elsevier.com/a/1ivNN3QE--Z9…

Table 👇 with trials in MGUS&smoldering myeloma

I summarize reasons why such trials are problematic&can harm patients

Samer Al Hadidi, MD,MS,FACP If an IRB truly understood how bad our risk stratification models are, and how much better the natural history of SMM is compared to older historical data, they would never approve such studies, IMO.

Excellent editorial by Samer Al Hadidi, MD,MS,FACP about use of T-cell redirecting therapy in myeloma precursor conditions.

Tox of talquetamab can be horrendous- my patients recall it long after moving on to diff treatment.

I disagree with studying it in MGUS/SMM

tinyurl.com/4uvs444s

Check our recent article: Targeting GPRC5D in multiple myeloma #mmsm UAMS Myeloma Center led by Dr Shatha Elemian from 🇯🇴 (Internal medicine resident interested in hematology-Oncology fellowship) Hem-Onc Fellows Network

Free access for first 50:
➡️ tandfonline.com/doi/full/10.10…

Summary tables 👇

#EBMT24 Bored between sessions and feel like the cacophony around carfilzomib dosing in myeloma #MMsm has become molto FORTE?

Help us standardize our field's practice!

12 questions, <3 min. 🙏 to physicians from 28 countries who've already responded!

redcap.link/carfilzomib

Check our recent article: Targeting GPRC5D in multiple myeloma #mmsm UAMS Myeloma Center led by Dr Shatha Elemian from 🇯🇴 (Internal medicine resident interested in hematology-Oncology fellowship) Hem-Onc Fellows Network

Free access for first 50:
➡️ tandfonline.com/doi/full/10.10…

Summary tables 👇

Check Vumedi talk on: CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent FDA ODAC Meeting. #mmsm UAMS Myeloma Center

vumedi.com/video/car-ts-e…

Our Samer Al Hadidi, MD,MS,FACP with a thread on a FDA Oncology discussion about minimal residual disease for #MultipleMyeloma #mmsm

PRO’s should be required with every studied that is approved for accrual. Having both efficacy and QOL data will help patients make informed decisions based upon their individual preferences. #mmsm

Imp. slide on the summary of trial-level correlation between MRD and PFS/OS across the disease spectrum in #Myeloma . IMO, key takeaway here is that MRD is NOT a good surrogate endpoint in most settings. (Ofc, has other utilities eg potential tool for Rx modification, prognosis)

Check out my editorial: Clinical Trials of T-Cell Re-Directing Therapy in Plasma Cell Precursor Conditions #mmsm

➡️free access: authors.elsevier.com/a/1ivNN3QE--Z9…

Table 👇 with trials in MGUS&smoldering myeloma

I summarize reasons why such trials are problematic&can harm patients

Fantastic episode discussing the data with Samer Al Hadidi, MD,MS,FACP on the two now FDA-approved BCMA CAR T-cell therapy products for relapsed multiple myeloma. Raj Chakraborty and Eddie Cliff, thank you for bringing out this episode! Blood Cancer Talks 💯